Lung carcinomas with a basaloid pattern: A study of 90 cases focusing on their poor prognosis

European Respiratory Journal

Volumn 31, Issue 4, 2008, Pages 854-859

  Moro Sibilot, D ^a,b   Lantuejoul, S ^a,b   Diab, S ^b   Moulai, N ^b   Aubert, A ^a,b   Timsit, J F ^a,b   Brambilla, C ^a,b   Brichon, P Y ^a,b   Brambilla, E ^a,b  

^a INSERM   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

Basaloid carcinoma; Diagnosis and staging; Lung cancer; Pathology

Indexed keywords

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CLASSIFICATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 42949111133     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00058507     Document Type: Article

References (24)

1. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Human Pathol 1992; 23: 993-1003.
2. Sarbia M, Verreet P, Bittinger F, et al. Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 1997; 79: 1871-1878.
3. Kawashima O, Kamiyoshihara M, Sakata S, Kurihara T, Ishikawa S, Morishita Y. Basaloid carcinoma of the thymus. Ann Thorac Surg 1999; 68: 1863-1865.
4. Andreadis D, Nomikos A, Epivatianos A, Poulopoulos A, Barbatis C. Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. Pathology 2005; 37: 560-563.
5. Teramoto N, Nishimura R, Saeki T, Nogawa T, Hiura M. Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma. Pathol Int 2005; 55: 445-452.
6. Wain SL, Kier R, Vollmer RT, Bossen EH. Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol 1986; 17: 1158-1166.
7. Moro D, Brichon PY, Brambilla E, Veale D, Labat F, Brambilla C. Basaloid bronchial carcinoma: a histological group with a poor prognosis. Cancer 1994; 73: 2734-2739.
8. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34βE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001; 32: 918-925.
9. Brambilla E. Basaloid carcinoma. In: Brambilla C, Brambilla E, eds. Lung Tumors: Fundamental Biology and Clinical Management. New York, Marcel Dekker, 1998; pp. 55-68.
10. Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumors. 3rd Edn. Geneva, World Health Organization, 1999.
11. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, International Agency for Research on Cancer, 2004.
12. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-2852.
13. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15: 529-553.
14. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22: 934-944.
15. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003; 27: 311-324.
16. Kim DJ, Kim KD, Shin DH, Ro JY, Chung KY. Basaloid carcinoma of the lung: a really dismal histologic variant? Ann Thorac Surg 2003; 76: 1833-1837.
17. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1777.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
19. Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Controlled Clin Trials 1996; 17: 343-346.
20. Arriaguda R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
21. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
22. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
23. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
24. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007; 25: 2735-2740.